Clinical Trials Browser

Withdrawn × infigratinib × Clear all

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1 Withdrawn

Gastrointestinal

Liver Neoplasms, Cholangiocarcinoma

NCT05222165 2023-02-23

NEWEL

Phase 1/2 Withdrawn

Central Nervous System Neoplasms

NCT04972253 2022-08-10

(BLASST)-3

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms

NCT02312804 2015-02-16

Ph Ib/BGJ398/Cervix and Other Solid Tumors

Phase 1 Withdrawn

Uterine Cervical Neoplasms, Neoplasms